Case studies
Financial statements
We combine cutting-edge science with a deep understanding of customer needs to drive innovation. Our commitment to service, quality and excellence is embedded in every aspect of our operations, fostering trust, confidentiality, and seamless collaboration.
Established in 1993, Syngene is a fully integrated organization offering end-to-end scientific solutions across research, development, and commercial production. With expertise in both small and large molecules, we serve global pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries.
Our strong track record in customer satisfaction, scientific innovation and operational excellence has made us a trusted partner for multinational corporations, emerging biotech firms, academic institutions, non-profit organizations, and government agencies.
We offer flexible, customized partnership models, spanning from specialist services to long-term strategic programs.
With a relentless focus on quality and excellence, we are continually investing in world-class talent, state-of-the-art infrastructure, and advanced technology. By embracing digital transformation, strengthening supply chain resilience, and optimizing operational processes, we are setting new benchmarks in efficiency, productivity, and compliance.
Beyond business performance, we remain committed to sustainability and responsible corporate citizenship. Our ESG initiatives focus on reducing our carbon footprint, ensuring workplace safety, and making a positive impact in the communities where we operate. As a publicly listed company on the Indian stock exchanges, we uphold the highest standards of transparency, governance, and long-term value creation.
With more than 8,200 employees and workers, including over 5,600 scientists, our workforce underpins the success of our operations. Specialists and professionals across various functions ensure seamless project execution, while our focus on scientific integrity, compliance, and high performance aligns every team member with our core values and objectives.
Our headquarters and main campus, serving as the central hub for research, development, and manufacturing, are located in Bengaluru, India. Large-molecule development and manufacturing take place at our main campus, complemented by a newly operational multi-modal biologics manufacturing unit (Unit 3). In addition, we operate three satellite campuses in Bengaluru that support key corporate functions, including Human Resources, Legal, and Finance, alongside our Clinical Development facility. To meet the growing demands of our research operations, we have expanded to Hyderabad, while our Mangaluru facility specializes in the commercial-scale production of active pharmaceutical ingredients (APIs).
We recently expanded our global footprint with the acquisition of a biologics manufacturing facility in Baltimore, Maryland, United States, further strengthening our presence in large molecule development and production. Additionally, Syngene U.S. Inc. supports our customers in the United States, complemented by commercial teams strategically positioned in the United Kingdom and Europe.
*This is a representative selection of the customers Syngene works with. We work with over 400 customers across industry segments
*All product names, logos, brands, trademarks and registered trademarks are the property of their respective owners
Our Research Services division supports the full spectrum of early-stage R&D, from target identification to clinical transition. This integrated division brings together Discovery Chemistry, Discovery Biology, Translational & Clinical Research and Dedicated R&D Centers.
Our Dedicated R&D Centers offer a comprehensive solution for customers seeking large-scale research facilities without major long‑term capital investment. These centers function as an extension of our customers’ internal research network, providing seamless integration while offering operational flexibility. Each center is staffed with a dedicated, multi-disciplinary team of scientists and support personnel, ensuring efficient project execution.
Our expertise spans small molecules, biologics, and advanced modalities such as peptides, oligonucleotides, antibody-drug conjugates, and targeted protein degradation/stabilization thus enabling end-to-end solutions that accelerate drug development.
Our Development Services division takes forward promising candidates from the Research Services pipeline, with a focus on small molecules. We provide end-to-end support from pre-clinical development through clinical trial readiness, specializing in drug substance and drug product development. Our capabilities ensure safety, tolerability, and efficacy through rigorous testing and validation.
We also work with next-generation modalities, including antibody-drug conjugates (ADCs), oligonucleotides, and peptides, ensuring a smooth, science-driven transition from development to GMP-compliant manufacturing with a focus on efficiency and sustainability.
Additionally, we work with performance chemicals and specialty materials, leveraging expertise in synthetic, organic and polymer chemistry. Integrated analytical services support every stage of development, covering method development, validation, transfer, and reference standard qualification.
The Company’s CDMO Services specialize in the development, scale-up and manufacturing of drug products for clinical trials and commercial distribution. They offer a range of services that include drug development, process development, analytical testing, formulation development, scale-up, manufacturing, packaging and distribution. These services can be provided on a standalone basis, or as part of a complete end-to-end service offering.
Small molecule manufacturing is carried out at our USFDA‑compliant API facility in Mangaluru, ensuring high-quality and regulatory-compliant production.
Large molecule development and manufacturing take place at our biologics facility in Bengaluru, which is approved by U.S. and European regulatory authorities. Additionally, we have a multi-modal biologics manufacturing facility, set to become operational in FY26. To strengthen our global biologics capacity, we recently acquired a state-of-the-art manufacturing facility in the United States, expanding our ability to serve customers across regions with greater flexibility and scale.
We understand that every customer has unique requirements, which is why we offer flexible and customizable collaboration models. Customers can select a single option or integrate multiple offerings to create tailored solutions that align with their specific needs and project goals.
